Sort
48,018 grants matching “immunotherapy”
Epitope-Specific Targeting of Tau Aggregates
$677,295Einar M Sigurdsson · New York University School Of Medicine · R01 · FY2022 · NS
Epitope-Specific Targeting of Tau Aggregates
$677,295Einar M Sigurdsson · New York University School Of Medicine · R01 · FY2023 · NS
Epitope-Specific Targeting of Tau Aggregates
$677,295Einar M Sigurdsson · New York University School Of Medicine · R01 · FY2024 · NS
Epitope-Specific Targeting of Tau Aggregates
$677,295Einar M Sigurdsson · New York University School Of Medicine · R01 · FY2025 · NS
Interstitial Chemophototherapy as an Intervention in Locally Advanced Pancreatic Cancer
$677,176Jonathan F Lovell · State University Of New York At Buffalo · R01 · FY2025 · CA
Translational, statistical, and clinical trials core
$676,826Julie R Park · Children'S Hosp Of Philadelphia · P01 · FY2024 · CA
Biomarkers and Therapeutic Targets in Angiogenesis and Metastasis
$676,757Rosandra Kaplan · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA
Clinical Protocol and Data Management (Core 018)
$676,693Elizabeth C Dees · Univ Of North Carolina Chapel Hill · P30 · FY2017 · CA
Integrated blood and radiomic subtyping to guide immunotherapy treatment selection and early response assessment in metastatic non-small cell lung cancer
$676,561Natalie Vokes · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA
Prebiotic diet intervention to enhance the microbiome and immunotherapy response in melanoma
$676,478Carrie Daniel-Macdougall · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA
Assessing benefits and harms of cannabis use in patients treated with immunotherapy for cancer: a prospective cohort study
$676,418Rebecca Ashare · State University Of New York At Buffalo · U01 · FY2023 · CA
AUTOIMMUNITY: TREATMENT BY COSTIMULATORY SIGNAL BLOCKADE
$676,340Brigham And Women'S Hospital · U19 · FY2001 · AI
Development of Physiologic Tissue Models to Assess Tumor Explant Response to Immune Checkpoint Blockade
$676,329Roger D. Kamm · Massachusetts Institute Of Technology · U01 · FY2020 · CA
Defining immune-evasive mechanical signaling in head and neck cancer
$676,314Xaralabos Varelas · Boston University Medical Campus · R01 · FY2025 · DE
Targeted radiation and immunocytokine therapy for CEA positive malignancies
$676,263John E. Shively · Beckman Research Institute/City Of Hope · R01 · FY2023 · CA
Targeted radiation and immunocytokine therapy for CEA positive malignancies
$676,263John E. Shively · Beckman Research Institute/City Of Hope · R01 · FY2025 · CA
Optimizing methods of clinical sample processing for scRNA-seq and mechanistic studies in sepsis to enable reliable, reproducible, and high-yield multi-center collection efforts
$676,179Michael Filbin · Massachusetts General Hospital · R33 · FY2025 · GM
Clinical Protocol and Data Management
$676,114Kari Braun Wisinski · University Of Wisconsin-Madison · P30 · FY2024 · CA
Clinical Protocol and Data Management
$676,114Kari Braun Wisinski · University Of Wisconsin-Madison · P30 · FY2023 · CA
Clinical Protocol and Data Management
$676,114Kari Braun Wisinski · University Of Wisconsin-Madison · P30 · FY2025 · CA
A single-arm phase II study to evaluate the safety and efficacy of combination systematic chemotherapy and multiple rounds of endoscopic ultrasound-guided radiofrequency ablation in pancreatic cancer
$676,081Jennifer Bailey Lundberg · University Of Texas Hlth Sci Ctr Houston · R01 · FY2023 · CA
Novel approaches to target KEAP1 mutant tumors
$676,063Thales Papagiannakopoulos · New York University School Of Medicine · R01 · FY2024 · CA
Early identification of immunotherapy resistance through integrated multiparameter imaging
$676,006Mekhail Anwar · University Of California, San Francisco · R01 · FY2025 · CA
IL-2 Family Cytokines and their Receptors-- Biology of the IL-2 system
$675,999Warren J Leonard · National Heart, Lung, And Blood Institute · ZIA · FY2010 · HL
Detection of PD-1 inhibitory signaling and its molecular relays in T cells: Implications for cancer immunotherapy
$675,994Vassiliki A Boussiotis · Beth Israel Deaconess Medical Center · R01 · FY2024 · CA